Conclusion: This systematic review of large observational studies suggests that the procedural stroke/death risks of CEA, but not CAS, have decreased significantly.
Carotid artery stenting yields lower restenosis rates compared to redo carotid endarterectomy for recurrent carotid artery stenosis Key findings: After propensity matching of 148 consecutive interventions for post-CEA restenosis, 32 carotid artery stenting (CAS) interventions were matched with 32 redo carotid endarterectomies (CEAs). All redo CEAs were performed with polyurethane patch closure. Seven patients who were treated with common carotid (CCA) to internal carotid artery (ICA) bypass were excluded. There were no perioperative deaths or strokes and no significant differences in terms of stroke-free survival between the two groups. However, cranial nerve palsy occurred in seven patients in the redo CEA group. In the CAS group vs the redo CEA group, freedom from secondary restenosis at 4 years were 100% vs 72.5% (P ¼ .005; log rank, 7.9) and freedom from secondary reintervention were100% vs 83%, respectively (P ¼ .02; log rank, 4.8) respectively.
Conclusion: Although CAS and redo CEA in patients with post-CEA restenosis had similar low perioperative stroke rates and stroke-free survival, CAS patients had lower rates of local nerve injury, secondary restenosis and reinterventions than redo CEA patients.
Commentary: Many of us might expect that redo CEA would have better long-term patency rates than CAS to treat recurrent carotid stenosis. Experience with lower extremity failing vein grafts has shown that repair of a stenotic lesion with a vein patch or interposition vein graft yields superior patency rates compared to endovascular intervention (although wound complication rates are higher with surgery). But repair of recurrent carotid artery stenosis after CEA may not be the same animal. Often these lesions cannot be repaired with a vein patch because the resultant intimal hyperplasia is so severe that a patch will not restore full luminal diameter and an interposition graft is required. However, many patients are prone to develop recurrent intimal hyperplasia within or at the anastomoses of the interposition grafts. One would think the same recurrent intimal hyperplasia would develop in a stent, but this study and others suggest otherwise. I have three criticisms of the paper. First, the authors only included patients who underwent surgery with redo CEA patching and excluded patients treated with CCA-ICA bypasses, which would likely yield better patency rates in many of these cases. Second, redo CEAs were all performed with polyurethane patches and not vein patches. I use autologous vein for redo CEA to potentially decrease intimal hyperplasia (and decrease infection). Third, and most importantly, they used different duplex ultrasound criteria to define >80% recurrent carotid stenosis, namely a peak systolic velocity (PSV) greater than 225 cms/sec after redo CEA and 340 cms/sec after CAS. Although a higher PSV should be used for recurrent CAS stenosis, I would never use PSV > 225 cms/sec as the sole criteria to define more than 80% carotid stenosis (unless I wanted to dramatically increase my CEA volume by operating unnecessarily on asymptomatic patients). Nonetheless, although there are some reports showing excellent long-term patency rates of redo carotid surgery, I agree with the authors that CAS is the way to go to treat recurrent carotid stenosis after CEA in most patients.
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